U.S. markets open in 14 minutes

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.94-0.16 (-1.13%)
At close: 4:00PM EDT

Mersana Therapeutics, Inc.

840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020

Full Time Employees110

Key Executives

NameTitlePayExercisedYear Born
Ms. Anna ProtopapasPres, CEO & Director881.5kN/A1964
Mr. Brian C. DeSchuytnerSr. VP of Fin. & Product Strategy580.01kN/A1978
Dr. Timothy B. LowingerChief Science & Technology Officer606.13k1.25M1964
Dr. Michael KaufmanChief Manufacturing Officer590.23kN/A1958
Dr. Arvin Yang M.D., Ph.D.Sr. VP & Chief Medical Officer533.54kN/A1976
Mr. Mikhail Papisov Ph.D.Co-FounderN/AN/AN/A
Mr. Ashish MandeliaVP, Controller & Principal Accounting OfficerN/AN/A1974
Ms. Sarah CarmodyExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Alejandra Veronica CarvajalSr. VP & Chief Legal OfficerN/AN/A1974
Ms. Carla PoulsonChief HR OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Mersana Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.